Choosing the right username can be surprisingly difficult. Whether you are creating a new gaming profile, joining an online community, setting up a social ...

Tryptyr. Vizz. Enflonsia. Anzupgo. New drug names make it sound like pharmaceutical companies throw a bunch of syllables into ...

There is a version of you that only strangers get to meet. The one standing at a gate desk about to lose it, or working a ...

Adding two or three of your actual roster players almost always produces sharper results than searching for a single star. But to produce the best results for your season, make sure you practice with ...

You did the draft prep, you got the players you wanted and the 2026 NFL season is almost here. There’s just one thing missing from your perfect fantasy football team: a name. Can’t think of anything ...

The start of NFL training camps means the new season is (finally) just around the corner. More importantly, it means that it's time to gear up for fantasy football drafts. While many diehards are ...

Create unique usernames in seconds for all your online accounts. We always emphasize the importance of strong passwords, but that’s only part of the equation. Your usernames also play a role in ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...